South Korea aims to develop mRNA vaccine by next year – South Korea aims to develop mRNA vaccine by next year

“Our goal is to develop the mRNA vaccine by next year with the technologies acquired through a potential technology transfer and co-development deal,” Young-Rai, a spokesman for the Ministry of Health and Welfare, said in a radio interview.

New Delhi. The South Korean government aims to develop the mRNA vaccine by next year. The country aims to strengthen its vaccine production capacity and move forward as a global vaccine manufacturing hub, an official said on Monday. At the same time the messenger RNA vaccine technology has to be protected. “Our goal is to develop the mRNA vaccine by next year with the technologies acquired through a potential technology transfer and co-development deal,” Young-Rai, son of a spokesman for the Ministry of Health and Welfare, said in a radio interview on Monday.

Also Read: – Leaflet Positive News: Voluntary Organizations Open Second Covid Care Center, 24 Hour Doctor – All Treatment Arrangements Including Oxygen

The deal was signed in Washington last week
Let me tell you that this comment came at a time when Samsung Biologics of Korea was preparing to begin the process of filling and finishing for its state-of-the-art COVID-19 vaccine, MRNA 1273, at its plant in Songado. Under the deal, which was signed in Washington last week, the Korean firm will take drugs imported from elsewhere. Will put it in vials and package the vials for shipment.

Also read: – Scientists build cheap oxygen concentrator, three liters of oxygen will be ready in a minute

No Korean company has mRNA technology
The Korean government is also expected to take advantage of the partnership with Morden to help local development of the mRNA vaccine. Messenger RNA technology is considered more advanced than traditional vaccine techniques based on viral vectors. No Korean company has mRNA technology. Samsung Biologics is the first Korean company to deal with the mRNA-type COVID-19 vaccine. However this is only for the fill-finishing process. Moderna has developed only two mRNA vaccines, one of which is Pfizer-Bionotech.

Moderna said in April that the company would increase production at several facilities next year to produce 3 billion doses of its COVID-19 vaccine. The company later noted that the investment would enable Lonza to double its production in vaccine material manufacturing facilities in Switzerland. Korea could benefit in the short term by handling the filling and packaging of Samsung Biologics Modern Jobs, as it wants to secure more doses to vaccinate the local population, Health Ministry official Sone said.

Related Articles

Back to top button